| Factor XIII in severe sepsis and septic shock. | |
| | |
MedLine Citation:
|
PMID: 16574200 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: In sepsis, activation of coagulation and inhibition of fibrinolysis lead to microvascular thrombosis. Thus, clot stability might be a critical issue in the development of multiple organ dysfunction syndrome. Activated FXIII (FXIIIa) forms stable fibrin clots by covalently cross-linking fibrin monomers. Therefore, we investigated the impact of FXIII antigen and activity levels on disease severity and fatality in sepsis patients. PATIENTS AND METHODS: FXIII subunit A (FXIIIA) and FXIII cross-linking activity (FXIIICA) were measured in 151 controls, in 32 patients with severe sepsis and 8 with septic shock. In addition, FXIII subunit B (FXIIIB) was measured in the sepsis patients. Moreover, clotting parameters were determined. RESULTS: Patients suffering from sepsis (n=40) had significantly (p<0.005) lower FXIIIA levels (median [range]: 36.5% [8.8-127.4%]) and FXIIICA levels (76.5% [9.4-266%]) as compared to healthy controls (n=151, 119% [31.3-283.2] and 122.4% [40.6-485.3], respectively). No difference in FXIIIA, FXIIIB and FXIIICA levels between survivors and non-survivors, nor between patients with severe sepsis and septic shock was found. The specific activity of FXIII (FXIIICA/FXIIIA, SA(FXIII)) was significantly (p<0.001) higher in sepsis patients (2.0 [0.8-5.3]) as compared to healthy controls (1.0 [0.4-5.1]). SA(FXIII) significantly (p<0.05) increased with fatality (non-survivors [n=13] vs. survivors [n=27]: 3.3 [1.2-5.0] vs. 1.9 [0.8-5.3]) and disease severity (septic shock vs. severe sepsis: 3.4 [1.8-4.3] vs. 1.9 [0.8-5.3]). CONCLUSION: We show decreased FXIIICA and FXIIIA levels, but higher SA(FXIII) in sepsis as compared to controls. Increased SA(FXIII) correlates with disease severity and fatality in sepsis patients. |
| | |
Authors:
|
Sacha Zeerleder; Verena Schroeder; Bernhard Lämmle; Walter A Wuillemin; C Erik Hack; Hans Peter Kohler |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2006-03-30 |
Journal Detail:
|
Title: Thrombosis research Volume: 119 ISSN: 0049-3848 ISO Abbreviation: Thromb. Res. Publication Date: 2007 |
Date Detail:
|
Created Date: 2006-12-22 Completed Date: 2007-04-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0326377 Medline TA: Thromb Res Country: United States |
Other Details:
|
Languages: eng Pagination: 311-8 Citation Subset: IM |
Affiliation:
|
Sanquin Research at CLB, Amsterdam, The Netherlands. s.zeerleder@sanquin.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Factor XIIIa
/
analysis* Female Fibrinolysis Humans Male Multiple Organ Failure / blood, etiology, mortality Shock, Septic / blood*, complications, drug therapy, mortality Survival Rate |
| Chemical | |
Reg. No./Substance:
|
EC 2.3.2.13/Factor XIIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence for the transfer of polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, and polyc...
Next Document: Prophylaxis in rare coagulation disorders -- factor X deficiency.